Lumipulse® G β-Amyloid 1-42

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of β-amyloid in human cerebrospinal fluid.  

This CSF biomarker is intended to be used as an aid for diagnosis in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.

    Contact sales for information
    Lumipulse® G β-Amyloid 1-42 Immunoreaction Cartridges

    Product number 230336

    3 x 14 Tests
    Lumipulse® G β-Amyloid 1-42 Calibrators

    Product number 230343

    2 x 3 Concentrations
    CE marked (IVDR)
    Please contact your local Fujirebio representative for the availability of this product in your country.
    Lumipulse G β-Amyloid 1-42 Immunoreaction Cartridges (230336) and Lumipulse G β-Amyloid 1-42 Calibrators (230343) Lumipulse G CLIA analyzer cartridge close up LUMIPULSE G1200 fully automated CLEIA analyzer - cartridge loading

    Click here to navigate

    • Contact sales for information
    • Details
    • Conditions of sale
    • Citations
    • Documentation
    • Insights
    • Product inquiry
    • Related products
    • Webinars

    • Details

       See the LUMIPULSE G1200 working in this video:

       

    • Conditions of sale

      To read the end user conditions of sale for this product please visit our Resource center.

    • Citations

      The BIOZ badges associated with Fujirebio products include peer-reviewed citations derived from scientific studies using Fujirebio products. Please note that the peer-reviewed citations do not reflect the regulatory status of Fujirebio products. Users should refer to the specific product documentation and any (clinical) claims made therein in order to ensure compliant use. For each country or geographic region, users must verify the related regulatory status of the Fujirebio product.

    • Insights

    • Product inquiry

      CAPTCHA

      The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

      For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

      If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.

      • Review past webinars

      Neurodegenerative diseases
      Replay available
      2026/03/03 - 10:00 AM EST / 16:00 CET

      Mapping Synaptic Loss: Where β‑synuclein Fits in the Biomarker Landscape

      Watch replay
      Neurodegenerative diseases
      Replay available
      2025/11/19 - 10:00 AM EST / 16:00 CET

      Unlocking the biology of dementia with Lewy bodies: Biomarker insights from DDC to synapses

      Watch replay
      Neurodegenerative diseases
      Replay available
      2021/11/18 - 18 November 2021

      Preparing for the future of plasma based Alzheimers disease diagnostics

      Watch replay

    Veuillez confirmer que vous êtes un professionnel de la santé

    Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

    Choose your country or region

    Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
    The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.